N-terminal pro-atrial natriuretic peptide as a biochemical marker of long-term interventional success after radiofrequency catheter ablation of paroxysmal supraventricular tachyarrhythmias

References

1 Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001; 39:571–88.10.1515/CCLM.2001.093Search in Google Scholar

2 Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin Chem Lab Med 2002; 40:752–60.10.1515/CCLM.2002.129Search in Google Scholar

3 Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195–203.10.1161/01.CIR.90.1.195Search in Google Scholar

4 Lerman , A, Gibbons RJ, Rodeheffer RJ, Bailey KR, McKinley LJ, Heublein DM, et al. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341:1105–9.10.1016/0140-6736(93)93125-KSearch in Google Scholar

5 Muders F, Kromer EP, Griese, DP, Pfeifer M, Hense HW, Riegger GA, et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am Heart J 1997; 134:442–9.10.1016/S0002-8703(97)70079-6Search in Google Scholar

6 Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular death. N Engl J Med 2004; 350:655–63.10.1056/NEJMoa031994Search in Google Scholar

7 Thibault G, Garcia R, Gutkowska J, Bilodeau J, Lazure C, Seidah NE, et al. The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic peptide. Biochem J 1987; 241:265–72.10.1042/bj2410265Search in Google Scholar

8 Sundsfjord JA, Thibault G, Larochelle P, Cantin M. Identification and plasma concentration of the N-terminal fragment of pro-atrial natriuretic factor in man. J Clin Endocrinol Metab 1988; 66:605–10.10.1210/jcem-66-3-605Search in Google Scholar

9 Nugent AM, Onuoha GN, McEneaney DJ, Steele IC, Hunter SJ, Prasanna K, et al. Variable patterns of atrial natriuretic peptide secretion in man. Eur J Clin Invest 1994; 24:267–74.10.1111/j.1365-2362.1994.tb01084.xSearch in Google Scholar

10 Thibault G, Murthy KK, Gutkowska J, Seidan NG, Lazure C, Chretien M, et al. NH2-terminal fragment of pro-atrial natriuretic factor in the circulation: identification, radioimmunoassay and half-life. Peptides 1988; 9:47–53.10.1016/0196-9781(88)90008-3Search in Google Scholar

11 McDowell G, Patterson C, Maguire S, Shaw C, Nicholls DP, Hall C. Variability of NT-proANP and ANP. Eur J Clin Invest 2002; 32:545–8.10.1046/j.1365-2362.2002.01031.xSearch in Google Scholar

12 Roy D, Paillard F, Cassidy D, Bourassa MG, Gutkowska J, Genest J, et al. Atrial natriuretic factor during atrial fibrillation and supraventricular tachycardia. J Am Coll Cardiol 1987; 9:509–14.10.1016/S0735-1097(87)80042-6Search in Google Scholar

13 Hall C, Rouleau JL, Moyè L, de Champlain J, Bichet D, Klein M, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89:1934–42.10.1161/01.CIR.89.5.1934Search in Google Scholar

14 Petersen P, Kastrup J, Vilhelmsen R, Schütten HJ. Atrial natriuretic peptide in atrial fibrillation after electrical cardioversion therapy. Eur Heart J 1988; 9:639–41.10.1093/oxfordjournals.eurheartj.a062554Search in Google Scholar

15 Mookherjee S, Anderson G, Smulyan H, Vardan S. Atrial natriuretic peptide response to cardioversion of atrial flutter and fibrillation and role of associated heart failure. Am J Cardiol 1991; 67:377–80.10.1016/0002-9149(91)90045-MSearch in Google Scholar

16 Hornestam B, Hall C, Held P, Carlsson T, Falk L, Karlson BW, et al. for the Digitalis in Acute Atrial Fibrillation (DAAF) Trial group. N-terminal proANF in acute atrial fibrillation: a biochemical marker of atrial pressures but not a predictor for conversion to sinus rhythm. Am Heart J 1998; 135:1040–7.10.1016/S0002-8703(98)70070-5Search in Google Scholar

17 Oliver JR, Twidale N, Lakin C, Cain M, Tonkin AM. Plasma atrial natriuretic polypeptide concentrations during and after reversion of paroxysmal supraventricular tachycardias. Br Heart J 1988; 58:458–62.10.1136/hrt.59.4.458Search in Google Scholar

18 Nilsson G, Pettersson A, Hedner J, Hedner T. Increased plasma levels of atrial natriuretic peptide (ANP) in patients with paroxysmal supraventricular tachyarrhythmias. Acta Med Scand 1987; 221:15–21.10.1111/j.0954-6820.1987.tb01240.xSearch in Google Scholar

19 Rossi A, Enriquez-Sarano M, Burnett JC, Lerman A, Abel MD, Seward JB. Natriuretic peptides in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol 2000; 35:1256–62.10.1016/S0735-1097(00)00515-5Search in Google Scholar

20 Madrid AH, del Rey JM, Rubi J, Ortega J, Gonzalez Rebollo JM, Seara JG, et al. Biochemical markers and cardiac troponin I release after radiofrequency catheter ablation: approach to size of necrosis. Am Heart J 1998; 136:948–55.10.1016/S0002-8703(98)70148-6Search in Google Scholar

21 Manolis AS, Vassilikos V, Maounis T, Melita-Manolis H, Psarros L, Haliasos A, et al. Detection of myocardial injury during radiofrequency catheter ablation by measuring serum cardiac troponin I levels: procedural correlates. J Am Coll Cardiol 1999; 34:1099–105.10.1016/S0735-1097(99)00330-7Search in Google Scholar

22 Abe H, Nagatomo T, Kobayashi H, Miura Y, Araki M, Kuroiwa A, et al. Neurohumoral and hemodynamic mechanisms of diuresis during atrioventricular nodal reentrant tachycardia. Pacing Clin Electrophysiol 1997; 20:2783–8.10.1111/j.1540-8159.1997.tb05436.xSearch in Google Scholar

23 Mattioli AV, Bonatti S, Bonetti L, Borella P, Mattioli G. Left atrial size and function after spontaneous cardioversion of atrial fibrillation and their relation to N-terminal atrial natriuretic peptide. Am J Cardiol 2003; 91:1478–81.10.1016/S0002-9149(03)00404-1Search in Google Scholar

24 Katritsis D, Hossein-Nia M, Anastasakis A, Poloniecki J, Holt DW, Camm AJ, et al. Myocardial injury induced by radiofrequency and low energy ablation: a quantitative study of CK isoforms, CKMB, and troponin-T concentrations. Pacing Clin Electrophysiol 1998; 21:1410–6.10.1111/j.1540-8159.1998.tb00212.xSearch in Google Scholar

25 Apple FS, Sharkey SW, Falahati A, Murakami M, Mitha N, Christensen D. Assessment of left ventricular function using serum cardiac troponin I measurements following myocardial infarction. Clin Chim Acta 1998; 272:59–67.10.1016/S0009-8981(97)00252-0Search in Google Scholar

26 Ellis K, Dresibach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 2001; 94:993–6.10.1097/00007611-200194100-00011Search in Google Scholar

27 Dagres N, Clague JR, Breithardt G, Borggrefe M. Significant gender-related differences in radiofrequency catheter ablation therapy. J Am Coll Cardiol 2003; 42:1103–7.10.1016/S0735-1097(03)00925-2Search in Google Scholar

28 Sakamoto T, Mizuno Y, Ogawa H, Yoshimura M, Kugiyama K, Yasue H. B-type natriuretic peptide after percutaneous transluminal septal myocardial ablation. Int J Cardiol 2002; 83:151–8.10.1016/S0167-5273(02)00035-9Search in Google Scholar

29 Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6:92–6.10.1016/S1071-9164(00)90010-1Search in Google Scholar

30 Ohta Y, Shimada T, Yoshitomi H, Inoue S, Murakami Y, Shimizu H, et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001; 17:415–20.Search in Google Scholar

31 Jourdain P, Bellorini M, Funck F, Fulla Y, Guillard N, Loiret J, et al. Short-term effects of sinus rhythm restoration in patients with lone atrial fibrillation: a hormonal study. Eur J Heart Fail 2002; 4:263–7.10.1016/S1388-9842(02)00004-1Search in Google Scholar

32 Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke 2002; 33:1005–10.10.1161/hs0402.105657Search in Google Scholar PubMed

33 Silvet H, Young-Xu Y, Walleigh D, Ravid S. Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Am J Cardiol 2003; 92:1124–7.10.1016/j.amjcard.2003.07.010Search in Google Scholar PubMed

34 Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction – comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004; 42:159–63.10.1515/CCLM.2004.029Search in Google Scholar PubMed

35 Mueller T, Gegenhuber A, Poelz W, Haltmeyer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003; 6:976–9.10.1373/49.6.976Search in Google Scholar PubMed